Evidence map›Paper›PMID 38156106›Full record

ArticleFrontiers in oncology2023

Lesion segmentation on

Tonghe Wang, Yang Lei, Eduard Schreibmann, Justin Roper, Tian Liu, David M Schuster, Ashesh B Jani, Xiaofeng Yang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. A review of artificial intelligence in brachytherapy.Journal of applied clinical medical physics · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tonghe WangDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Yang LeiDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Eduard SchreibmannDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Justin RoperDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Tian LiuDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
David M SchusterDepartment of Radiology and Imaging Science and Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Ashesh B JaniDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Xiaofeng YangDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer OutcomesR01CA226992 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2019 to 2023
$3.1M
eXtended Modular ANthropomorphic (XMAN) phantom for Imaging and Treatment Optimization in Radiotherapy.R01EB032680 · NIBIB · UNIVERSITY OF MARYLAND BALTIMORE · PI REN, LEI, YANG, XIAOFENG · 2022 to 2025
$2.4M
Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy RadiotherapyR01CA169188 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2012 to 2016
$2.1M
Multiparametric MRI-guided Prostate HDR Brachytherapy with Focal Tumor BoostR01CA215718 · NCI · EMORY UNIVERSITY · PI YANG, XIAOFENG · 2018 to 2022
$1.8M
Artificial Intelligence Driven Platform for PET/MR ImagingR56EB033332 · NIBIB · EMORY UNIVERSITY · PI MAO, HUI, YANG, XIAOFENG · 2022 to 2022
$764k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA169188NCI NIH HHS R01 CA215718NCI NIH HHS R01 CA226992NIBIB NIH HHS R01 EB032680NIBIB NIH HHS R56 EB033332
6 · The paper itself

Abstract

Background and purpose: A novel radiotracer, Materials and methods: We retrospectively identified 84 patients who are enrolled in Arm B of the Emory Molecular Prostate Imaging for Radiotherapy Enhancement (EMPIRE-1) trial. All 84 patients had prostate adenocarcinoma and underwent prostatectomy and Results: All three deep learning methods were able to detect 144/155 lesions and 153/155 lesions successfully when PET+CT and PET only, respectively, served as input. Quantitative results demonstrated that the neural network with the best performance was able to segment lesions with an average DSC of 0.68 ± 0.15 and HD95 of 4 ± 2 mm. The center of mass of the segmented contours deviated from physician contours by approximately 2 mm on average, and the volume difference was less than 1 cc. The novel network proposed by us achieves the best performance compared to current networks. The addition of CT as input to the neural network contributed to more cases of failure (DSC = 0), and among those cases of DSC > 0, it was shown to produce no statistically significant difference with the use of only PET as input for our proposed method. Conclusion: Quantitative results demonstrated the feasibility of the deep learning methods in automatically segmenting lesions on

Indexed as

deep learningneural networkPET/CTprostate radiotherapysegmentation

Identifiers

PMID38156106
PMCPMC10753832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.